•
The full guidance (this document).
• A quick reference guide for healthcare professionals.
• Information for people with heart failure and their carers ('Understanding NICE guidance').
• Details of all the evidence that was looked at and other background information.
For printed copies of the quick reference guide or 'Understanding NICE guidance', phone the NHS Response Line on 0870 1555 455 and quote:
• N1265 (quick reference guide) • N1266 ('Understanding NICE guidance').
This guidance is written in the following context
This guidance represents the view of the Institute, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. The guidance does not, however, override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Guidance
This guidance should be read in conjunction with 'Implantable cardioverter defibrillators for arrhythmias' (NICE technology appraisal guidance 95 -see appendix C). This guidance on cardiac resynchronisation therapy provides additional treatment options for some of the groups of people covered in the guidance on implantable cardioverter defibrillators (ICDs).
Cardiac resynchronisation therapy with a pacing device (CRT-P) is
recommended as a treatment option for people with heart failure who fulfil all the following criteria.
• They are currently experiencing or have recently experienced New York Heart Association (NYHA) class III-IV symptoms.
• They are in sinus rhythm:
− either with a QRS duration of 150 ms or longer estimated by standard electrocardiogram (ECG)
− or with a QRS duration of 120-149 ms estimated by ECG and mechanical dyssynchrony that is confirmed by echocardiography.
• They have a left ventricular ejection fraction of 35% or less.
• They are receiving optimal pharmacological therapy.
Cardiac resynchronisation therapy with a defibrillator device (CRT-D) may
be considered for people who fulfil the criteria for implantation of a CRT-P device in section 1.1 and who also separately fulfil the criteria for the use of an ICD device as recommended in NICE technology appraisal guidance 95.
Clinical need and practice

2.1
Heart failure is a complex syndrome that can result from any structural or functional cardiac disorder that impairs the heart's ability to function efficiently as a pump to support physiological circulation. In a healthy heart, the lower chambers (ventricles) pump at the same time and in NICE technology appraisal guidance 120synchrony with the upper chambers (atria). This appraisal considered the treatment of people with heart failure caused by left ventricular systolic dysfunction, in which the left ventricle fails to pump in synchrony with some or all of the other chambers of the heart. If the contractions lack synchrony (because of either poor atrioventricular synchrony or lack of synchrony between the two ventricles), the heart becomes less efficient as a pump.
2.2
The incidence and prevalence of heart failure increase steeply with age, and the average age at first diagnosis is 76 years. The incidence of heart failure in the UK is 140 per 100,000 men and 120 per 100,000 women.
Although the incidence is higher in men, evidence suggests higher mortality in women with the condition. Around 3% of people aged 65-74 years have heart failure; this increases to about 7% of those aged 75-84 years, and to just over 14% in those aged 85 years and older. The prevalence of heart failure in the UK is 40 per 1000 in men and 30 per 1000 in women.
2.3
Heart failure has a poor prognosis, with about 40% of patients dying within 1 year of diagnosis. More severely ill patients are more likely to die because of pump failure (congestive heart failure), while those with less severe heart failure are more likely to experience sudden cardiac death.
2.4
Heart failure is characterised by symptoms such as breathlessness, reduced exercise tolerance, fatigue and fluid retention, together with signs of reduced cardiac output. The extent to which the symptoms of heart failure affect quality of life can be measured using the New York Heart Association (NYHA) classification: from class I (no limitations) to class IV (inability to carry out any physical activity without discomfort). Among people with heart failure due to left ventricular systolic dysfunction, 27%
are in NYHA class I, 50% in class II, 11% in class III and 12% in class IV.
2.5
The diagnosis of heart failure is based on a combination of patient history, physical examination and appropriate investigations to assess cardiac NICE technology appraisal guidance 120function (chest X-ray, electrocardiography or tests for elevated plasma concentrations of brain natriuretic peptide). People with heart failure who can be considered for cardiac resynchronisation therapy (CRT) have a reduced left ventricular ejection fraction (the fraction of blood pumped out of the left ventricle with each heart beat expressed as a percentage of the total volume), and characteristic changes on an ECG (which measures electrical dyssynchrony) due to abnormal electrical conductivity.
Echocardiographic assessment, which measures aspects of mechanical dyssynchrony, can also be used to identify patients whose condition is likely to respond to CRT.
2.6
Treatment for heart failure aims to improve life expectancy and quality of life. Heart failure should initially be managed pharmacologically in accordance with the NICE clinical guideline 'Chronic heart failure: management of chronic heart failure in adults in primary and secondary care' (NICE clinical guideline 5). However, as the condition becomes more severe, symptoms may no longer be controlled by pharmacological treatment.
3
The technology
3.1
The aim of CRT (also known as biventricular pacing) is to improve the heart's pumping efficiency by resynchronising the pumping action of the chambers. CRT involves implantation in the upper chest of a pulse generator from which three leads descend via veins into the heart. Leads are placed in the right atrium and the right ventricle, and a third lead (the left ventricular lead) is usually placed via the coronary sinus. CRT pacing (CRT-P) devices allow both regulation of atrioventricular delay and restoration of synchronous contraction by pacing the right atrium and both ventricles. A cardioverter defibrillator function can be included with the pulse generator to defibrillate the heart internally should an acute arrhythmic event occur, and in this case the device is known as a CRT-D device.
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Evidence and interpretation
The Appraisal Committee (appendix A) considered evidence from a number of sources (see appendix B).
Clinical effectiveness
4.1.1 Literature searches identified a total of 10 studies of CRT compared with optimal pharmacological therapy: five systematic reviews and five randomised controlled trials (RCTs). In the RCTs, a total of 3434 patients were randomised to receive either CRT in addition to optimal pharmacological therapy, or optimal pharmacological therapy alone. Of 4.1.7 CARE-HF and COMPANION reported on the rate of death from heart failure and showed conflicting results: CARE-HF (n = 813) reported a statistically significant reduction in the incidence of death from heart failure for CRT-P compared with optimal pharmacological therapy alone, whereas COMPANION (n = 1520) reported no difference in treatment effect. Pooled analysis demonstrated a statistically significant reduction in death from heart failure for CRT-P compared with optimal pharmacological therapy alone (HR 0.62, 95% CI 0.46 to 0.83).
4.1.8 All four RCTs reported the incidence of sudden cardiac death. Only CARE-HF, the RCT with the longest follow-up, found a statistically significant difference between CRT-P and optimal pharmacological therapy alone. Meta-analysis of all four RCTs demonstrated no significant difference in the rate of sudden cardiac death for CRT-P compared with optimal pharmacological therapy alone (HR 0.75, 95% CI 0.45 to 1.18).
4.1.9 CARE-HF, MUSTIC-SR and MIRACLE reported on the rate of hospitalisation for heart failure, and the meta-analysis of these RCTs showed a statistically significant reduction in the rate of hospitalisation for CRT-P compared with optimal pharmacological therapy alone (pooled HR 0.48, 95% CI 0.37 to 0.61).
4.1.10 MIRACLE and CARE-HF found a statistically significant reduction in the risk of worsening heart failure for CRT-P compared with optimal pharmacological therapy (pooled HR 0.67, 95% CI 0.46 to 0.84). The MUSTIC-SR trial reported no significant difference in the risk of worsening heart failure for CRT-P compared with optimal pharmacological therapy.
4.1.11
Three RCTs (CARE-HF, COMPANION and MIRACLE) reported statistically significant improvements in NYHA class with CRT-P compared with optimal pharmacological therapy. All four RCTs showed consistent improvements in exercise capacity and health-related quality of life for CRT-P compared with optimal pharmacological therapy alone.
There was no difference in the rate of atrial arrhythmias. Subgroup analysis showed no difference in the effectiveness of CRT-P between patients with ischaemic and non-ischaemic heart failure. 
CRT-D versus
4.3.2
The Committee understood that the benefits of implantation of a CRT device are related to improvements in the symptoms of heart failure, the extension of life of those with heart failure and a reduction in the incidence of sudden cardiac death. The risk of sudden cardiac death is related to the presence of both heart failure associated with ventricular dyssynchrony and other underlying cardiac conditions that could add to the risk of sudden cardiac death. The Committee heard from clinical specialists that in patients with a diagnosis of heart failure associated with left ventricular systolic dysfunction, the use of CRT is based primarily on a diagnosis of electrical dyssynchrony as indicated by a widened QRS complex of more than 150 ms on a standard ECG. The Committee also understood from the clinical specialists that confirmation of the presence of mechanical dyssynchrony by echocardiography was considered appropriate in patients with electrical dyssynchrony as indicated by a QRS duration of between 120 ms and 149 ms. The Committee noted that this approach was the same as the inclusion criteria for the CARE-HF trial.
4.3.3
The Committee considered the inclusion criteria for patients entered into the RCTs identified, which included symptomatic heart failure at NYHA class II-IV, a QRS duration greater than 120 ms or 150 ms, and a left ventricular ejection fraction of less than 35%. All of these RCTs excluded patients with atrial fibrillation. Clinical specialists advised that most patients included in the RCTs had a QRS duration greater than 150 ms, and that patients who have a greater degree of electrical dyssynchrony (QRS duration greater than 150 ms) may derive more benefit from CRT.
The Committee was aware that there is uncertainty as to the exact mechanism of this benefit and of the direct relationship between the degree of dyssynchrony and the degree of benefit derived from CRT-P.
The Committee also heard from the clinical specialists that echocardiography alone is not a good predictor of response to CRT, and agreed that QRS duration should be the primary criterion by which patient eligibility for CRT is determined. The Committee noted that in one of the large studies (CARE-HF) additional evidence of mechanical dyssynchrony from echocardiography was required in patients with a QRS duration of between 120 ms and 150 ms, and was therefore persuaded that such a requirement would be appropriate to use in clinical practice.
4.3.4
The Committee was aware that the severity of the symptoms of heart failure, as indicated by the NYHA class, may vary from day to day.
However, it accepted that on average the NYHA class is relatively stable over the medium term and will tend to worsen over the long term. The
Committee was persuaded that patients with current or recent NYHA class III and IV symptoms (similar to the patients enrolled in the principal clinical trials) would derive most benefit from CRT.
4.3.5
The Committee considered there to be insufficient evidence on the effectiveness of CRT in patients with heart failure associated with atrial fibrillation for it to make recommendations for this group, and emphasised the need for further research on the effectiveness of CRT in these patients.
4.3.6
The Committee considered the evidence from RCTs, clinical specialists and patient experts on the benefits and risks of CRT compared with optimal pharmacological therapy alone. The Committee concluded that the implantation of a CRT-P or CRT-D device led to significant improvements in all-cause mortality, hospitalisation for heart failure and health-related quality of life compared with optimal pharmacological therapy alone. The Committee heard from the clinical specialists that some patients with heart failure who initially have a CRT-P device inserted may require an upgrade to a defibrillator (CRT-D) device because of the progression of underlying disease and the emergence of additional risk of sudden cardiac death.
4.3.7
The Committee noted that the only evidence on the effectiveness of CRT-D compared with CRT-P was based on the results of the COMPANION trial, which was not powered to detect a difference between the two device types. However, the Committee agreed that there is sufficient evidence from this trial to suggest that the incidence of sudden cardiac death is lower after CRT-D device implantation than after CRT-P device implantation. The Committee heard from the clinical specialists that implantation of a CRT-P device is more technically challenging than for standard pacemaker devices, and that implantation of a CRT-D device is even more so. In addition, the success of implantation increases with operator experience.
4.3.8
The Committee additionally heard from the clinical specialists that CRT-D devices may deliver inappropriate defibrillating shocks, which may be distressing for patients and impair their quality of life, especially for patients who are at low risk of sudden cardiac death. The Committee understood that the risks and benefits of the use of a defibrillator device would need to be evaluated on a case-by-case basis.
4.3.9
The Committee heard from the clinical specialists that the decision whether to implant a CRT-D or a CRT-P device usually depends on whether the patient has additional risk factors for sudden cardiac death, over and above those associated with cardiac dyssynchrony, which might have led them to consider the use of an ICD. The Committee was also mindful that people who have a CRT-P device implanted may go on to develop additional risk factors for sudden cardiac death and thus might require an upgrade to a CRT-D device.
4.3.10
The Committee noted that a proportion of patients (11-46%) who have a CRT device implanted successfully do not respond to treatment. The clinical specialists advised that this occurs either because the leads, in particular the left ventricular lead, are not at the optimal site for ventricular stimulation, or because the condition of some patients fails to respond to CRT. The Committee understood that there was no definitive evidence relating to clinical factors that would allow patients whose condition might not respond to be identified before the device is implanted.
4.3.11
The Committee reviewed all data on the cost effectiveness of CRT in the manufacturers' and Assessment Group's models. The Committee 5.3 NICE has developed tools to help organisations implement this guidance (listed below). These are available on our website (www.nice.org.uk/TA120).
• Local costing template incorporating a costing report to estimate the savings and costs associated with implementation.
• Audit criteria to monitor local practice.
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Appendix B. Sources of evidence considered by the Committee A. The assessment report for this appraisal was prepared by Peninsula
Technology Assessment Group, Universities of Exeter and Plymouth.
• • Association of British Healthcare Industries (ABHI)
• EUCOMED
• Medicines and Healthcare products Regulatory Agency (MHRA)
• NHS Quality Improvement Scotland 
